Type I interferon (IFN) enhances the transcription of the tumor suppressor gene p53. To elucidate the molecular mechanism mediating IFN-induced apoptosis, we analysed programmed cell death in response to type I (IFNa) or type II (IFNc) treatment in relation to p53 status. In two cell lines (MCF-7, SKNSH), IFNa, but not IFNc, enhanced apoptosis in a p53-dependent manner. Furthermore, only IFNa upregulated p53 as well as p53 target genes (Noxa, Mdm2 and CD95). The apoptotic response to IFNa decreased in the presence of ZB4, an anti-CD95 antibody, suggesting that CD95 is involved in this process. When p53 was inactivated by the E6 viral protein or the expression of a p53 mutant, IFNa-induced apoptosis and p53 target genes upregulation were abrogated. Altogether these results demonstrate that p53 plays a pivotal role in the IFNa-induced apoptotic response. IFNa-induced PML was unable to recruit p53 into nuclear bodies and its downregulation by siRNA did not alter CD95 expression. In contrast, IFNc-induced apoptosis is p53-independent. CD95 and IFN-regulatory factor 1 (IRF1) are directly upregulated by this cytokine. Apoptotic response to IFNc is decreased in the presence of ZB4 and strongly diminished by IRF1 siRNA, implicating both CD95 and IRF1 in IFNc-induced apoptotic response. Taken together, these results show that in two different cell lines, IFNa and IFNc, induce p53-dependent -independent apoptosis, respectively. Oncogene (2005) 24, 605-615.
Introduction
Interferons (IFNs) constitute a large family of multifunctional secreted proteins that share antiviral, antitumor and immunomodulatory activities (Stark et al., 1998) . IFNs, classified as a, b, o, g on the basis of their structure and antigenic proprieties, are grouped into two families: type I and type II IFNs. IFN a, b, o, which belong to the type I family, are produced by most cell types in response to viral infection, double-stranded RNA or other stimuli (Stark et al., 1998) . IFNg, the only member of the type II family, is secreted by T lymphocytes and NK cells in response to specific antigens or mitogens (Pfeffer et al., 1998) . Type I and type II IFNs interact with distinct cell surface receptors, resulting in the activation of specific Janus protein kinase (JAK)/signal transducers and activators of transcription (STAT) pathways, leading to the transcription of a distinct set of genes that mediate the biological responses of these cytokines. The consensus sequences GAAAN(N)GAAA (IFN-stimulated response element (ISRE)) and TTNCNNNAA (IFNgactivated site, gamma-activating sequence (GAS)) present within the promoter regions of IFN-responsive genes confer type I and type II IFN inducibility, respectively. Although IFNs inhibit the proliferation of a variety of tumor cells (Strander, 1986; Wadler and Schwartz, 1990; Koshiji et al., 1997; Hadden, 1999) and activate several genes encoding proapoptotic proteins such as promyelocytic leukemia gene (PML), dsRNAdependent protein kinase (PKR), TNF-related apoptosis-inducing ligand (TRAIL), CD95 (Fas/APO-1) and IFN-regulatory factor 1 (IRF1) (Barber, 2001) , the relationship between these IFN-induced proteins and apoptotic pathways remains to be determined.
The tumor suppressor p53 plays a pivotal role in the regulation of the cell cycle. Several agents, which induce DNA damage, such as ionizing and UV radiation, 5-fluorouracil, activate p53 that promotes cell cycle arrest or apoptosis through transcriptional activation of its target genes (Prives and Hall, 1999; Vogelstein et al., 2000; Vousden and Lu, 2002) . Although p53 gene expression is induced directly by IFNb (Takaoka et al., 2003) , its precise role in type I IFN-induced apoptosis remains unknown.
PML is another tumor-suppressor and proapoptotic protein (Wang et al., 1998) upregulated by type I and type II IFNs (Regad and Chelbi-Alix, 2001 ). Seven isoforms of PML (PML I-VII) are produced by alternative splicing from a single gene (Jensen et al., 2001 ), but their specific functions remain largely unexplored. All the PML isoforms (except PML VII) are localized in the nucleus, both in the nucleoplasm and in the nuclear bodies (NBs), a nuclear matrix associated with multiprotein complexes. Localization of PML in NBs is dependent upon its post-translational modification by SUMO (Small Ubiquitin MOdifier) and is essential for the formation of these structures (Sternsdorf et al., 1997; Kamitani et al., 1998; Muller et al., 1998b) . Overexpression of PML IV induces the recruitment of p53 into NBs and acts as a transcriptional co-activator probably by stimulating post-translational modifications of p53 (Fogal et al., 2000) . Indeed, PML-mediated recruitment of p53 and CBP, a histone acetyltransferase, or the homeodomain-interacting protein kinase-2 (HIPK2) within the NBs, induces the formation of p53-PML-CBP or p53-PML-HIPK2 complexes, resulting in stimulation of p53 acetylation or phosphorylation and increased p53 transcriptional activity (Guo et al., 2000; Pearson et al., 2000; D'Orazi et al., 2002; Hofmann et al., 2002) .
CD95, a member of the tumor necrosis factor receptor family, is another potent inducer of apoptosis, which is upregulated by type I and type II IFNs. After interaction with its natural ligand (CD95L), CD95 recruits pro-caspase-8 via the adapter protein FADD (Fas-associated death domain) and subsequently activates the caspases cascade that leads to DNA fragmentation and apoptosis (Muzio et al., 1996; Bischof et al., 2002) . Several studies suggest that p53 regulates the transcription of CD95 (Bennett et al., 1998; Muller et al., 1998a) , and a p53-responsive element has been detected within the first intron of the human (Muller et al., 1998a) and mouse (Munsch et al., 2000) CD95 genes.
IFNg enhances the expression of IRF1, a transcription factor involved in regulation of the cell cycle, apoptosis and tumor growth (Kim et al., 2004) . In addition, IRF1 may also regulate an additional pathway that suppresses tumorigenesis in a p53-independent manner (Nozawa et al., 1999; Taniguchi et al., 2001) . The above data prompted us to analyse the role of p53, PML, CD95 and IRF1 in the IFN apoptotic-signaling pathways. We show here that CD95 activation mediates both type I and type II IFN-induced apoptosis. Furthermore, induction of both CD95 expression and apoptosis by IFNa, but not by IFNg, is p53-dependent. PML was unable to recruit p53 into NBs following IFN treatment, and downregulation of PML using small interfering RNA (siRNA) did not affect CD95 expression induced by IFNa or IFNg. Finally, both the CD95 and IRF1 pathways appear to be important mediators of IFNg-induced apoptosis.
Results

IFNa-but not IFNg-induced apoptosis is dependent upon the presence of wild-type p53
In order to analyse the apoptotic response to types I and II IFNs in relation to p53 status, human breast carcinoma cell lines containing wild-type p53 (MCF-7) or p53 inactivated by HPV16/E6 expression (MCF-7/E6) were treated with IFNa or IFNg. The number of apoptotic cells was determined in each case by Annexine V and propidium iodide (PI) staining. Following treatment with IFNg, the percentage of apoptotic cells in MCF-7 and MCF7/E6 cell lines was not significantly different. In contrast, IFNainduced apoptosis was abrogated in MCF7/E6 cells ( Figure 1a) . Similar results were obtained in a human neuroblastoma cell line expressing wild-type p53 (SKNSH) or a dominant-negative p53 mutant (SKNSH DD) (Figure 1b) (Ruiz-Ruiz et al., 2000) . Similar responses were also obtained when cells were treated for 48 h with higher doses of IFNa or IFNg (10 000 U/ml, data not shown). Interestingly, the percentage of cells undergoing apoptosis increased with the time of IFNa treatment and reached 25 and 42% after 72 and 96 h, respectively (Figure 1c ). In these conditions also, IFNa-induced apoptosis was abolished in cells containing inactivated p53 (Figure 1c ). These data show that IFNa-induced apoptosis required the expression of a wild-type p53.
IFN-induced PML is localized principally in the nucleoplasm and is unable to recruit p53 into NBs Localization of p53 and PML in IFNa-treated MCF-7 cells was analysed by confocal microscopy. Although p53 ( (Takaoka et al., 2003) and Figure 3a ) and PML expressions are both increased following treatment with IFNa, PML was unable to recruit p53 into NBs (Figure 2a) . The same results are obtained in IFNa-treated U2OS cells (data not shown). Since arsenic has been reported to enhance the capacity of PML IV to recruit p53 into NBs, p53 and PML localization was analysed following combined treatment with IFNa and arsenic. Colocalization of p53 and PML in NBs was not observed in these conditions (Figure 2a ) or when p53 was activated transcriptionally in the presence of 5-fluorouracil, a p53-activating drug (data not shown). In contrast, p53 was recruited by PML into NBs following transfection of U2OS cells with a plasmid expressing PML IV (Figure 2a) .
We have then determined the subcellular localization of PML isoforms induced in IFN-treated cells by Western blot analysis of cytoplasmic, nucleoplasmic (RIPA soluble) and nuclear matrix (RIPA insoluble) fractions. Both IFNa and IFNg enhance PML expression in the cytoplasm and in the nucleoplasm, but not in the nuclear matrix (Figure 2b ). Conjugation of PML to SUMO1, which is enhanced by arsenic, is critical for PML targeting to the nuclear matrix and recruitment of other NBs-associated proteins such as p53 (Zhu et al., 1997; Muller et al., 1998b) . We next examined whether PML and p53 distributions are effected in response to arsenic. In agreement with the immunofluorescence data ( Figure 2a) , treatment of cells with arsenic was found to shift IFN-induced PML towards the nuclear matrix (assessed by the RIPA insoluble fraction) without altering the cytoplasmic or nucleoplasmic localization of p53 (Figure 2c ). Taken together, these results show clearly that the IFNa-induced PML, in MCF-7 cells, is unable to recruit p53 to the NBs. Probably, PML IV is not induced to a significant extent in IFNatreated cells.
p53 and p53 target genes, Mdm2 and Noxa, are increased in response to treatment with IFNa but not IFNg
In agreement with a previous report showing that IFNb induces p53 gene expression (Takaoka et al., 2003) , treatment of MCF-7 cells with IFNa, but not IFNg, resulted in a clearcut increase in p53 mRNA expression determined by quantitative RT-PCR (Figure 3a) . A recent study reports that, in mouse embryonal fibroblasts, the induction of p53 by IFNb requires Bars, Mean and s.d. from at least three independent experiments and the statistical significance (P-values) were calculated using Student's t-test Implication of CD95, p53 and IRF1 in IFN-induced apoptosis C Porta et al ARF expression (Sandoval et al., 2004) . Thus, we determined p53 mRNA expression by quantitative RT-PCR in human U2OS cells that do not express ARF. We demonstrated, however, that in U2OS cells p53 is induced by IFNa but not by IFNg (Figure 3a) .
Furthermore, quantitative RT-PCR analysis of RNA extracted from MCF-7 cells showed that the p53 target genes Mdm2 and Noxa were induced by IFNa ( Figure 3b ). In contrast, the levels of Mdm2 and Noxa mRNAs in MCF-7/E6 cells containing inactivated p53 were unaffected by the same treatment (Figure 3b ), demonstrating that induction of these genes by IFNa is dependent upon the presence of wild-type p53.
CD95 expression induced in response to IFNa, but not to IFNg, is dependent upon the presence of wild-type p53
In addition to p53, IFNs modulate the expression of a number of proapoptotic genes (CD95, CD95L, Bak, Figure 2 IFN-induced PML is unable to recruit p53 into NBs. MCF-7 or U2OS cells were treated as indicated in Figure 1 , and PML and p53 proteins were detected by confocal microscopy using monoclonal anti-p53 and rabbit anti-PML antibodies followed by fluorescein conjugated anti-mouse IgG and rhodamine conjugated anti-rabbit IgG antibodies, respectively. (a) MCF-7 cells treated with IFNa, combined treatment with IFNa for 24 h together with 1 mM As 2 O 3 . U2OS cells transfected with a plasmid expressing PML IV (lower panel). (b) Analysis of PML protein expression after IFN treatment. MCF-7 cells were treated with IFNa or IFNg for 24 h. Cytoplasmic (C), RIPA soluble (R) and RIPA insoluble (P) fractions were analysed by Western blot with anti-PML antibody. (c) Arsenic induces PML but not p53 transfer from the nucleoplasm to the matrix. MCF-7 cells, pretreated with IFNa for 24 h, were treated with 1 mM As2O3 for 16 h. C, R and P fractions were analysed by Western blot for PML and p53 expressions (Panaretakis et al., 2003; Li et al., 2004; Wang et al., 2004) . To elucidate the relationship between these genes and p53 expression in the pathway(s) leading to IFN-induced apoptosis, the expression of these genes was analysed in IFN-treated MCF-7 and MCF-7/E6 cells using semiquantitative RT-PCR. Both IFNa and IFNg were found to upregulate IRF1 and Bak expression and to downregulate Bcl-2 expression in MCF-7 and MCF-7/ E6 cells while CD95L expression was unaffected (data not shown). IFNg also enhanced CD95 expression in both MCF-7 and MCF-7/E6 cells while IFNa induced CD95 in MCF-7 cells only (Figure 4a ), suggesting that CD95 induction by IFNa is p53-dependent. In order to confirm these results, we have analysed the capacity of IFN to induce CD95 expression in cells in which p53 expression was downregulated by interference RNA. Due to the difficulties encountered in transfecting MCF-7 and SKNSH cells, U2OS cells were transfected with p53 siRNA or unrelated siRNA, treated with IFNa or IFNg and analysed for both p53 and CD95 expression. p53 expression was completely downregulated in the presence of p53 siRNA both in control and IFN-treated cells (data not shown and Figure 6b ).
The level of CD95 mRNA was determined using semiquantitative RT-PCR. Both IFNa and IFNg induced CD95 expression in U2OS cells. In cells transfected with p53 siRNA, increase of CD95 mRNA by IFNg was not affected, whereas that by IFNa was highly decreased (Figure 4b) .
In order to determine whether PML is involved in IFNa-induced p53 activation, IFN-treated U2OS cells transfected with PML-specific or unrelated siRNA were analysed for CD95 expression by semiquantitative RT-PCR. PML downregulation did not alter CD95 expression induced by both types of IFN (Figure 4c ). Taken together, these results show that in U2OS cells, IFNs increase CD95 expression in a PML-independent manner. In order to determine whether induction of CD95 by IFNg is dependent upon the presence of the transcription factor IRF1 which exhibits proapoptotic activity, CD95 expression was evaluated by semiquantitative RT-PCR in U2OS cells transfected with IRF1-specific or unrelated siRNA and treated with IFNa or IFNg. Downregulation of IRF1 expression did not affect the ability of either 
Role of CD95 in IFNa-and IFNg-induced apoptosis
To determine whether CD95 is involved in the mechanism(s) by which IFNs induce apoptosis, extracellular expression of CD95 was analysed in MCF-7 cells treated with IFNa or IFNg. Both IFNs increased CD95 expression at the cell surface relative to untreated control cells (Figure 5a) . Furthermore, the percentage of apoptotic cells observed following treatment with either IFNa or IFNg was reduced in MCF-7 cells in the presence of ZB4, an anti-CD95 antibody (Figure 5b) .
To determine how IFNs promote CD95-induced apoptosis, caspase-8 and -9 enzymatic activities were analysed in IFN-treated MCF-7 cells. After IFNa or IFNg treatment, the cell lysates were tested for protease activity by the addition of a caspase specific peptide (IETD or LEHD) conjugated to the chromogenic pnitroalanine (pNA). The results of these studies show that the activity of both caspase-8 and -9 are increased following treatment with either IFNa or IFNg (Figure 5c ).
Role of IRF1 in IFNg-induced apoptosis
We next examined if IFNg induced cell death in U2OS cells. Similar results were obtained by using Annexin V/ IP staining or the caspase 3/7 activated detection kit (data not shown). Treatment with IFNg for 48 h induced apoptosis in U2OS cells (Figure 6 ) with higher levels of apoptosis induced during longer time of IFNg treatment (data not shown).
Interference RNA was used to study the role of the proapoptotic gene products, PML, p53 and IRF1, in IFNg-induced apoptosis. U2OS cells, transfected with PML siRNA, p53 siRNA, IRF1 siRNA or unrelated siRNA, were treated with IFNg and then analysed for expression of the specific protein and apoptosis. Treatment of U2OS cells with IFNg markedly increased the expression of several PML isoforms with molecular weights ranging from 66 to 130 kDa (Figure 6a) . Transfection of U2OS cells with PML siRNA reduced the expression of all the PML isoforms in both IFNgtreated and untreated cells (Figure 6a ). Since interference RNA has been reported to induce certain IFN-stimulated genes (ISG) (Bridge et al., 2003; Sledz et al., 2003) , Stat1 expression was analysed by Western blotting. Stat1 expression was not induced by unrelated or PML siRNA in control cells and its expression was similarly upregulated by IFNg treatment in both transfected cells (Figure 6a ), demonstrating that in our system siRNA did not induce these ISGs. The expression of p53 was also completely down- Implication of CD95, p53 and IRF1 in IFN-induced apoptosis C Porta et al regulated in the presence of p53 siRNA both in control and IFN-treated cells (Figure 6b ). The apoptosis induced by IFNg was not significantly different when the expression of PML or p53 were downregulated by siRNA (Figure 6a, b) . In contrast, downregulation of IRF1 expression by siRNA decreased apoptosis in response to IFNg (Figure 6c ), suggesting that this transcription factor may play a pivotal role in mediating apoptosis by this cytokine.
Discussion
Proteins encoded by IFN-responsive genes are the primary effectors of the IFN-mediated biological response. Induction of apoptosis by type I and II IFNs in multiple cell lines from varied histologies has been reported to involve caspase-8 signaling, activation of the caspase cascade, release of cytochrome c from mitochondria, disruption of mitochondrial potential and DNA fragmentation (Ossina et al., 1997; Chen et al., 2001; Thyrell et al., 2002) . Studies using microarrays have led to the identification of more than 15 putative ISGs with proapoptotic functions including Bak, CD95, PML, PKR or IRF1 (Der et al., 1998) .
IFN-induced apoptosis occurs late (X48 h) after initiation of treatment, suggesting that intermediate cellular effector(s) or genes activated by IFNs are involved in the establishment of apoptosis. In this report, we show that in MCF-7 and SKNSH cells, the induction of apoptosis by IFNa, but not IFNg, is dependent on the expression of wild-type p53. IFN a/b (Takaoka et al., 2003) , but not IFNg (this report), has recently been shown to enhance transcription of the p53 gene. Takaoka et al. (2003) reported that IFNb induces p53 gene transcription directly through the activation of ISGF3 which binds to the ISRE. Furthermore, a recent study indicates that in mouse embryonal fibroblasts, the induction of p53 by IFNb could require ARF (Sandoval et al., 2004) . In this report, we demonstrated by quantitative RT-PCR analysis that p53 is induced by IFNa in U2OS cells that do not express ARF. However, no significant apoptosis was induced by IFNa or IFNb in U2OS cells ((Sandoval et al., 2004) and data not shown), suggesting that in specific cell types the induction of apoptosis by type I IFNs could require an ARF pathway.
Although serine phosphorylation of p53 in response to type I IFN was not observed (Takaoka et al., 2003 , and data not shown), we show, however, that expression of p53 target genes, such as CD95, Mdm2 and Noxa, were increased in IFNa-treated human cells and that this increase was dependent on the expression of wildtype p53. Such an increase was not observed in mouse cells treated with IFNb (Takaoka et al., 2003) . Although it has been reported recently that p53 can activate PML directly through the presence of a p53 consensus element localized within the first intron of PML (de Stanchina et al., 2004) , type I and type II IFNs are able to induce PML expression directly via GAS and ISRE recognition elements present within the PML promoter , suggesting that IFNs and p53 modulate PML expression by different mechanisms. Indeed, PML expression is induced similarly following IFN treatment in cells containing wild type or inactivated p53 (data not shown). IFNs induce directly PML expression so highly that it could mask PML increase by p53. Several reports (Cuddihy et al., 1999; Fogal et al., 2000; Guo et al., 2000; Pearson et al., 2000; Townsend et al., 2004) indicate that PML as well as other ISG products including Stat1 and PKR may also modulate p53 activity. Indeed, the C-terminal domain of PML interacts with the DNA-binding domain of p53, colocalizes with p53 in PML-NBs and acts as a p53 transcriptional co-activator (Fogal et al., 2000; Guo et al., 2000; Pearson et al., 2000) . Strikingly, p53 activation by PML is NBs dependent, and indeed a PML mutant that does not localize in the NBs, but still interacts with p53 and CBP, is unable to co-activate p53 transcription (Guo et al., 2000) . Thus, PML modulates Implication of CD95, p53 and IRF1 in IFN-induced apoptosis C Porta et al p53 function at least in part through PML NBs, which in turn potentiate its proapoptotic activity. Among the seven known isoforms of PML, only PML IV is able to recruit p53 and cause premature senescence, a process that involves p53 stabilization and activation (Pearson et al., 2000; Bischof et al., 2002; Ferbeyre, 2002; Bernardi and Pandolfi, 2003) .
In this report, we show that the different PML isoforms induced by IFNa were localized in the nucleoplasm and were unable to recruit p53 within NBs, even when both PML targeting to the nuclear matrix and p53 activation were increased by arsenic and 5-fluorouracil, respectively. Furthermore, the capacity of IFNa to increase CD95 expression is not altered by PML knockdown. Taken together, these results suggest that PML IV is poorly induced by IFNa in MCF-7 and U2OS cells and that Stat1 (Townsend et al., 2004) and/ or PKR (Cuddihy et al., 1999) could participate in p53 activation in response to treatment with IFNa and ultimately in the increase in the expression of p53 responsive target genes.
We also show that both IFNa and IFNg are able to enhance CD95 expression and that this process requires functional p53 in the case of IFNa and is p53-independent in the case of IFNg. In contrast, the IFNg-induced increase in CD95-mediated apoptosis is partially abrogated in the presence of antisense IRF1 oligodeoxynucleotide (Tomita et al., 2003) . Even though CD95 can be induced directly by IFNg (Der et al., 1998) , it was considered interesting to determine whether IRF1 also plays a role in CD95 upregulation. We found that IFNg-induced CD95 expression is unaltered by IRF1 siRNA, suggesting that CD95 is not an IRF1 target gene. Furthermore, CD95 appears to be an important mediator of both IFNa and IFNg-induced apoptosis since a significant decrease in the percentage of apoptotic cells was observed when CD95 activation was blocked by treatment with ZB4. We have also shown that IFNa, as well as IFNg, is able to activate caspases-8 and -9. Altogether these results suggest that IFNa and IFNg enhance CD95 expression by different pathways.
In addition to CD95, IRF1 seems to be an important mediator of IFNg-induced apoptosis. The results of several studies suggest that IRF1 exerts a proapoptotic function. Thus, IRF1
À/À cells have been shown to be resistant to apoptosis induced by DNA damage or IFNg treatment (Tanaka et al., 1994; Tamura et al., 1995; Kano et al., 1999) . Also, IRF1 overexpression has recently been shown to inhibit markedly the proliferation of breast cancer cells (Kim et al., 2004) . We show here that downregulation of IRF1 expression in IFNgtreated U2OS cells markedly impaired the apoptotic response to IFNg, suggesting that IRF1 may be the pivotal mediator of IFNg-induced apopotosis. In addition, the increase of caspase-8 in IFNg-treated MCF-7 cells requires the induction and action of IRF1 (RuizRuiz et al., 1999) . These results led us to propose the model presented in Figure 7 . The tumor suppressor p53 is induced directly by IFNa and probably activated by IFNa gene products, such as Stat1 or PKR. p53 plays a pivotal role in IFNa-induced apoptosis through transcriptional activation of CD95 and other target genes. CD95 activation promotes apoptosis either through activation of the caspase cascade and/or the mitochondriamediated pathway. On the contrary, IFNg induces apoptosis in a p53-independent manner. CD95 and IRF1 are directly upregulated by IFNg leading to caspase activation. The apoptotic response to IFNg is decreased in the presence of ZB4 and strongly decreased in cells transfected with IRF1 siRNA. Taken together. these results demonstrate that CD95 and IRF1 participate in IFNg-induced apoptosis.
Materials and methods
Cell culture and antibodies
The U2OS (derived from a human osteosarcoma), MCF-7 (derived from a human breast carcinoma) and SKNSH (human neuroblastoma) cells express wild-type p53. These three cell lines were grown in Dulbecco's modified Eagles's medium, (DMEM) supplemented with 10% fetal calf serum. MCF-7/E6 cells expressing HPV16/E6 protein (Fan et al., 1995) and SKNSH DDp53 cells expressing a truncated mouse p53 gene including amino-acid residues 1-14 and 302-390 under the control of the CMV promoter (Smart et al., 1999) were grown in the same medium supplemented with 200 mg/ml neomycin. Anti-human CD95-blocking monoclonal immunoglobulin G1 (IgG1) antibody (ZB4) was obtained from Upstate Biotechnology, Lake Placid, NY, USA) and 
IFNs cell treatment and RNA interference transfections
For all the experiments, cells were treated with 1000 U/ml of IFNa or IFNg. Human recombinant IFNg (specific activity 2 Â 10 7 U/mg) is from Roussel Uclaf (Romainville, France) and human recombinant IFNa2b (specific activity 2.04 Â 10 8 U/mg) is from Schering-Plough (Kenilworth, NJ, USA). The sense and antisense oligonucleotides (21 nucleotide-long) for siRNA were synthesized and annealed by Proligo (Boulder, CO, USA). The mRNA sequence to be targeted by siRNA selected are for PML (5 0 -AUGGCUUCG ACGAGUUCAATT-3 0 ), for p53 (5 0 -GCAUGAACCGGA GGCCCAUTT-3 0 ) and for IRF1 (5 0 -AGACCAGAGCAGG AACAAGTT-3 0 ). U2OS cell transfections were performed in six-well plates using the lipofectamine 2000 reagent (Life technologies, Paisley, UK) according to the manufacturer's instructions.
Apoptosis assays
Apoptotic cells were analysed by flow cytometry after Annexin V and Propidium Iodide staining (BD Biosciences, San Diego, CA, USA) or the use of the CaspaTagt CASPASE-3, 7 in situ assay kit FLUORESCEIN (CHEMICON international, Temecula, CA, USA) according to the manufacturer's protocols. Using a FACScalibur (Becton Dickinson) cytometer. Flow cytometry data were analysed using CellQuest software (Becton Dickinson). Caspase-8 and -9 colorimetric activity assay (R&D Systems, Abingdon, UK) was performed with 100 mg of total protein extracts according to the manufacturer's recommendations. Cleavages of the IETD-pNA and LEHD-pNA substrates by caspase-8 or -9, respectively, were measured at 405 nm.
Immunofluorescence and confocal microscopy
Cells were fixed in 4% paraformaldehyde for 20 min at 41C and permeabilized for 10 min with 0.1% Triton X-100 in PBS. They were then prepared for double-immunofluorescence staining and analysed by confocal microscopy. p53 was stained using DO1 or DO7 antibodies and anti-mouse IgG antibody conjugated to fluorescein. PML was detected with a rabbit anti-PML antibody and anti-rabbit IgG antibody conjugated to rhodamine. Confocal microscopic analysis was carried out using a Leica DMIRBE microscope.
Cell fractionation and Western blot analysis
Cells were dissociated and washed twice in PBS by centrifugation at 1200 g for 5 min. The cytoplasmic fraction was obtained by lysing the equivalent of 10 6 cells in 50 ml of Tris-HCl 1 M pH 7.5, NP40 0.5%, 20 min at 41C. Cells were then centrifuged at 1200 g for 15 min to separate nuclei (pellet) from the cytosol (C). Nucleoplasm was extracted from nuclei by incubating the pellet for 20 min on ice in RIPA buffer (50 mM Tris, pH 7.5/ 200 mM NaCl/1% Triton X-100/0.5% deoxycholate/0.1% SDS/1 mM EDTA), followed by centrifugation at 15000 g for 15 min to separate the RIPA soluble fraction (R) from the pellet (P). The RIPA insoluble fraction (P) was washed two times in RIPA buffer, suspended in PBS and boiled in Laemmli buffer. Protein extracts were analysed on a 10% SDS-PAGE as previously described with anti-PML, anti-Stat1, anti-p53, anti-IRF1 or anti-Actin antibodies. To estimate the apparent molecular mass of the polypeptides, the proteins of interest were compared to prestained molecular weight standards (BioRad laboratories, Richmond, CA, USA).
RNA isolation and semiquantitative RT-PCR
Total RNA was extracted from 10 7 cells (Chomczynski and Sacchi, 1987) and reverse transcribed using the first-strand cDNA synthesis kit, according to the manufacturer's instructions (Amersham Biosciences, Orsay, France). The PCR reaction was carried out with cDNA as template, 50 pmol of both primers in the reaction mixture (50 mM KCl, 10 mM TrisHCl pH 8.3, 1.5 mM MgCl 2 , 0.1% TritonX-100, 0.4 mM each dNTP (Promega, Madison, WI, USA), 2.5 U AmpliTaq polymerase (Applied Biosystems, Foster City, CA, USA)). After denaturation at 941C for 5 min, the samples underwent 25 cycles of amplification (1 min at 951C; 1 min at 53.51C for bactin or 601C for CD95; 1 min at 721C). Sense and antisense primers were: 5 0 -TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3 0 and 5 0 -CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3 0 for b-actin, and 5 0 -TCC AAG GGA TTG GAA TTG AG-3 0 and 5 0 -ACC TGG AGG ACA GGG CTT AT-3 0 for CD95. PCR products were electrophoresed on 1.5% agarose gel. Semiquantitative analysis was performed by the Gel Doc 2000 System (Bio-Rad). CD95 cDNA was normalized to b-actin cDNA concentration and CD95/actin cDNA ratios were calculated.
Real-time quantitation mRNA
For p53, Mdm2 and Noxa mRNA quantification, cDNA synthesis was performed using oligo dT (Sigma, St Louis, MO, USA) and AMV reverse transcriptase as described by the manufacturer (Promega). Real-time quantitative PCR was performed using the FastStart DNA Master SYBR Green I kit and the LightCycler apparatus according to the protocol provided by the manufacturer (Roche Molecular Biochemicals, Indianapolis, IN, USA). PCR was carried out with the following oligonucleotide pairs: 5 0 -CCC AGC CAA AGA AGA AAC CA-3 0 and 5 0 -CTC GGA ACA TCT CGA AGC G-3 0 for p53; 5 0 -CGT GCC AAG CTT CTC TGT GA-3 0 and 5 0 -GTC CGA TGA TCC TGC TGA T-3 0 for Mdm2; 5 0 -AGT AGC TGG AAG TCG AGT GT-3 0 and 5 0 -AGG TTC CTG AGC AGA AGA GT-3 0 for Noxa and 5 0 -AGC TCA CTG GCA TGG CCT TC-3 0 and 5 0 -ACG CCT GCT TCA CCA CCT TC-3 0 for GAPDH. Results were normalized to GAPDH.
Abbreviations FADD, Fas-associated death domain; IFN, interferon; PML, promyelocytic leukemia-related gene/protein; APL, acute promyelocyic leukemia; NBs, nuclear bodies; PKR, RNAdependent protein kinase; HIPK2, homeodomain-interacting protein kinase 2; IRF1, IFN-regulatory factor 1; STAT, signal tranducer and activator of transcription; JAK, Janus kinase; ISRE, IFN-stimulated response element; GAS, gamma-activating sequence; SUMO, small ubiquitin modifier; siRNA, small interfering RNA; ISG, IFN-stimulated gene.
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